Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis

Panitumumab and bevacizumab have been widely used in combination with chemotherapy for patients with wild type RAS metastatic colorectal cancer (mCRC). Whether panitumumab or bevacizumab was the optimal option remained controversial. Thus, we conducted a meta-anaylsis to evaluate chemotherapy plus p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhigui, Huang, Yuqian, Zhao, Rui, Cui, Yaping, Zhou, Yong, Wu, Xiaoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764984/
https://www.ncbi.nlm.nih.gov/pubmed/29323221
http://dx.doi.org/10.1038/s41598-017-19001-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764984/
https://www.ncbi.nlm.nih.gov/pubmed/29323221
http://dx.doi.org/10.1038/s41598-017-19001-6

Ejemplares similares